Ontology highlight
ABSTRACT: Purpose
The receptor tyrosine kinase c-Met plays an important role in tumorigenesis and is a novel target for anticancer treatment. This phase I, first-in-human trial, explored safety, pharmacokinetics, pharmacodynamics, and initial antitumor activity of JNJ-38877605, a potent and selective c-Met inhibitor.Experimental design
We performed a phase I dose-escalation study according to the standard 3+3 design.Results
Even at subtherapeutic doses, mild though recurrent renal toxicity was observed in virtually all patients. Renal toxicity had not been observed in preclinical studies in rats and dogs. Additional preclinical studies pointed toward the rabbit as a suitable toxicology model, as the formation of the M10 metabolite of JNJ-38877605 specifically occurred in rabb
SUBMITTER: Lolkema MP
PROVIDER: S-EPMC4433755 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature